ABBV enters the first week of June trading at $215.40, up roughly 1% on the week, with options positioning still leaning bullish and the Street's consensus target implying a further 17% upside — even as short sellers continue their slow, quiet rebuild.
The options story remains the dominant signal, and it has now held this tone for nearly two weeks. The put/call ratio has eased slightly to 0.94, still running about one standard deviation below its 20-day average of 1.00. That is a notable shift from the pattern that prevailed through April and into early May, when the PCR sat consistently above 1.0 and puts dominated. The rotation toward calls accelerated after the April 29 earnings beat — when the stock jumped 6.9% in a single session and then added another 3.7% over the following five days — and has not meaningfully reversed. The PCR has not been this consistently skewed toward calls since the 52-week low of 0.62 last June, though the current reading is well off that extreme. For the most part, call buyers have held control.
Short interest is moving in the opposite direction, and slowly. The short position has climbed about 8% over the past month to roughly 22.5 million shares, or 1.3% of the free float. The week-on-week gain is just over 1.6%. These are not crowded-short numbers — at this level, short interest is a sideshow rather than a thesis. What makes it worth noting is the direction: sellers have been adding steadily since late April, even as the stock climbed from the low $200s. Borrow conditions offer no friction at all. Availability is effectively unlimited, with more than 1.2 billion shares in the lending pool against a short position of 22 million. Cost to borrow is below 0.4%, down about 7% on the week. Nothing in the lending market discourages new short positions.
The Street remains firmly constructive, though the most recent analyst action is slightly mixed on price targets. Morgan Stanley raised its target to $278 after the Q1 beat, while Piper Sandler bumped to $298 — both maintaining positive ratings. Evercore ISI trimmed one point to $235 last month but kept Outperform. The consensus target of $252.90 implies meaningful upside from current levels, and the bull case centres on Skyrizi and Rinvoq momentum, next-generation ADC pipeline development, and multiple Phase 3 readouts ahead. Bear-case concerns focus on pricing risk in immunology and the competitive dynamics that could erode Skyrizi and Rinvoq margins over the medium term. On valuation, the trailing PE is running near 14.3x, and EV/EBITDA at 12.8x — neither extreme, though the price-to-book at 133x reflects the leverage embedded in this capital structure. The forward EPS growth rank sits at the 99th percentile, while the dividend score ranks at 98 — two data points that help explain why generalist holders stay patient through pipeline noise.
Institutional ownership is concentrated but broadly passive. BlackRock holds 8.5% of shares, Vanguard entities collectively account for another 9%+, and State Street holds nearly 4.6%. Capital Research is the largest active manager in the top holders, and trimmed around 11.5 million shares in the latest reported period — a worth-watching development that has not yet moved the needle on total institutional positioning. Among correlated peers, GILD fell 4.6% on the week and VRTX dropped 2.5%, underscoring that ABBV's mild gain reflects genuine relative resilience this week rather than sector tailwinds.
The next catalyst is the Q2 earnings print, currently scheduled for July 27. The prior quarter's 6.9% single-day gain reset the options market's tone; how the July print lands — particularly any update to Skyrizi volume trends and pipeline milestone timing — is the variable the market will be calibrating positioning against between now and then.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
